Beyond vaccines, RNA–lipid nanoparticle (LNP) nanomedicines have originally focused on cancer applications. This Review discusses how these therapeutics can also benefit acute critical illnesses (ACIs) owing to the short-term expression of mRNA while mitigating the adjuvant effect of LNPs, which, unlike in vaccines and cancer, can be a liability for ACIs.
- Serena Omo-Lamai
- Marco E. Zamora
- Jacob S. Brenner